AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Arcus Biosciences, Inc.
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00DQD2751
18.54▼ 0.82 (-4.24%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
19.36
Day's Range
18.43 – 19.09
52-Week Range
16.41 – 31.74
Volume
5.9M
Avg Volume
2.2M
Share Statistics
Shares Outstanding
Employees
601
Exchange
XNYS
Listed
2018-03-15
Share count as of July 30, 2026

Arcus Biosciences, Inc. (RCUS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Arcus Biosciences, Inc. (RCUS)
What is Arcus Biosciences, Inc.'s Market Cap?
Arcus Biosciences, Inc.'s Market Cap is $2.4B, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Enterprise Value?
Arcus Biosciences, Inc.'s Enterprise Value is $2.3B, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Price / Sales?
Arcus Biosciences, Inc.'s Price / Sales is 20.2×, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EV / Revenue?
Arcus Biosciences, Inc.'s EV / Revenue is 19.8×, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EV / EBITDA?
Arcus Biosciences, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Revenue (TTM)?
Arcus Biosciences, Inc.'s Revenue (TTM) is $117.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Net Income (TTM)?
Arcus Biosciences, Inc.'s Net Income (TTM) is -$460.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EBITDA?
Arcus Biosciences, Inc.'s EBITDA is -$476.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Diluted EPS (TTM)?
Arcus Biosciences, Inc.'s Diluted EPS (TTM) is -3.61, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EBITDA Margin?
Arcus Biosciences, Inc.'s EBITDA Margin is -406.8%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RCUSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth-74.4%-39.3%+26.9%-45.8%
Operating expenses:
Research and development (Includes $2, $11, $2 and $6 from a related party)
General and administrative (Includes $—, $2, $— and $2 from a related party)
Total operating expenses
% of revenue334.1%888.2%445.5%646.2%
Loss from operations
% of revenue-234.1%-788.2%-345.5%-546.2%
Non-operating income (expense):
Interest and other income, net
Interest expense
Total non-operating income, net
Income (loss) before income taxes
Income tax expense
Net income (loss)
% of revenue-222.0%-752.9%-321.2%-519.2%
Net income (loss) per share - basic (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)